Literature DB >> 21263136

Muscle histology vs MRI in Duchenne muscular dystrophy.

M Kinali1, V Arechavala-Gomeza, S Cirak, A Glover, M Guglieri, L Feng, K G Hollingsworth, D Hunt, H Jungbluth, H P Roper, R M Quinlivan, J A Gosalakkal, S Jayawant, A Nadeau, L Hughes-Carre, A Y Manzur, E Mercuri, J E Morgan, V Straub, K Bushby, C Sewry, M Rutherford, F Muntoni.   

Abstract

OBJECTIVE: There are currently no effective treatments to halt the muscle breakdown in Duchenne muscular dystrophy (DMD), although genetic-based clinical trials are being piloted. Most of these trials have as an endpoint the restoration of dystrophin in muscle fibers, hence requiring sufficiently well-preserved muscle of recruited patients. The choice of the muscles to be studied and the role of noninvasive methods to assess muscle preservation therefore require further evaluation.
METHODS: We studied the degree of muscle involvement in the lower leg muscles of 34 patients with DMD >8 years, using muscle MRI. In a subgroup of 15 patients we correlated the muscle MRI findings with the histology of open extensor digitorum brevis (EDB) muscle biopsies. Muscle MRI involvement was assigned using a scale 0-4 (normal-severe).
RESULTS: In all patients we documented a gradient of involvement of the lower leg muscles: the posterior compartment (gastrocnemius > soleus) was most severely affected; the anterior compartment (tibialis anterior/posterior, popliteus, extensor digitorum longus) least affected. Muscle MRI showed EDB involvement that correlated with the patient's age (p = 0.055). We show a correlation between the MRI and EDB histopathologic changes, with MRI 3-4 grades associated with a more severe fibro-adipose tissue replacement. The EDB was sufficiently preserved for bulk and signal intensity in 18/22 wheelchair users aged 10-16.6 years.
CONCLUSION: This study provides a detailed correlation between muscle histology and MRI changes in DMD and demonstrates the value of this imaging technique as a reliable tool for the selection of muscles in patients recruited into clinical trials.

Entities:  

Mesh:

Year:  2011        PMID: 21263136      PMCID: PMC3034418          DOI: 10.1212/WNL.0b013e318208811f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

1.  Magnetic resonance imaging of primary skeletal muscle diseases: patterns of distribution and severity of involvement.

Authors:  A E Lamminen
Journal:  Br J Radiol       Date:  1990-12       Impact factor: 3.039

Review 2.  Muscular Dystrophy Campaign Funded Workshop on Management of Scoliosis in Duchenne Muscular Dystrophy 24 January 2005, London, UK.

Authors:  Francesco Muntoni; Kate Bushby; Adnan Y Manzur
Journal:  Neuromuscul Disord       Date:  2006-02-23       Impact factor: 4.296

3.  149th ENMC International Workshop and 1st TREAT-NMD Workshop on: "planning phase i/ii clinical trials using systemically delivered antisense oligonucleotides in duchenne muscular dystrophy".

Authors:  Francesco Muntoni; Kate D Bushby; Gertjan van Ommen
Journal:  Neuromuscul Disord       Date:  2008-01-22       Impact factor: 4.296

4.  [Magnetic resonance imaging of skeletal muscle in patients with Duchenne muscular dystrophy--serial axial and sagittal section studies].

Authors:  H Nagao; T Morimoto; N Sano; M Takahashi; H Nagai; R Tawa; M Yoshimatsu; Y J Woo; H Matsuda
Journal:  No To Hattatsu       Date:  1991-01

5.  Local dystrophin restoration with antisense oligonucleotide PRO051.

Authors:  Judith C van Deutekom; Anneke A Janson; Ieke B Ginjaar; Wendy S Frankhuizen; Annemieke Aartsma-Rus; Mattie Bremmer-Bout; Johan T den Dunnen; Klaas Koop; Anneke J van der Kooi; Nathalie M Goemans; Sjef J de Kimpe; Peter F Ekhart; Edna H Venneker; Gerard J Platenburg; Jan J Verschuuren; Gert-Jan B van Ommen
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

6.  Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study.

Authors:  Tishya A L Wren; Stefan Bluml; Linda Tseng-Ong; Vicente Gilsanz
Journal:  AJR Am J Roentgenol       Date:  2008-01       Impact factor: 3.959

Review 7.  A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground.

Authors:  Toshifumi Yokota; Shin'ichi Takeda; Qi-Long Lu; Terence A Partridge; Akinori Nakamura; Eric P Hoffman
Journal:  Arch Neurol       Date:  2009-01

8.  A randomized controlled trial of early surgery in Duchenne muscular dystrophy.

Authors:  A Y Manzur; S A Hyde; E Rodillo; J Z Heckmatt; G Bentley; V Dubowitz
Journal:  Neuromuscul Disord       Date:  1992       Impact factor: 4.296

9.  [Asymmetrical patchy muscle involvement in manifesting carriers of Duchenne muscular dystrophy--computed tomographical and histological study].

Authors:  M Kawai; M Kunimoto; K Kamakura; T Masaki; K Watanabe
Journal:  Rinsho Shinkeigaku       Date:  1989-01

Review 10.  Genetic treatments in muscular dystrophies.

Authors:  Francesco Muntoni; Dominic Wells
Journal:  Curr Opin Neurol       Date:  2007-10       Impact factor: 5.710

View more
  63 in total

Review 1.  Magnetic resonance imaging patterns of muscle involvement in genetic muscle diseases: a systematic review.

Authors:  Doris G Leung
Journal:  J Neurol       Date:  2016-11-25       Impact factor: 4.849

2.  MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.

Authors:  Leo H Wang; Seth D Friedman; Dennis Shaw; Lauren Snider; Chao-Jen Wong; Chris B Budech; Sandra L Poliachik; Nancy E Gove; Leann M Lewis; Amy E Campbell; Richard J F L Lemmers; Silvère M Maarel; Stephen J Tapscott; Rabi N Tawil
Journal:  Hum Mol Genet       Date:  2019-02-01       Impact factor: 6.150

3.  Multi-parametric MRI characterization of healthy human thigh muscles at 3.0 T - relaxation, magnetization transfer, fat/water, and diffusion tensor imaging.

Authors:  Ke Li; Richard D Dortch; E Brian Welch; Nathan D Bryant; Amanda K W Buck; Theodore F Towse; Daniel F Gochberg; Mark D Does; Bruce M Damon; Jane H Park
Journal:  NMR Biomed       Date:  2014-07-26       Impact factor: 4.044

Review 4.  Striated muscle function, regeneration, and repair.

Authors:  I Y Shadrin; A Khodabukus; N Bursac
Journal:  Cell Mol Life Sci       Date:  2016-06-06       Impact factor: 9.261

5.  Activation of non-myogenic mesenchymal stem cells during the disease progression in dystrophic dystrophin/utrophin knockout mice.

Authors:  Jihee Sohn; Aiping Lu; Ying Tang; Bing Wang; Johnny Huard
Journal:  Hum Mol Genet       Date:  2015-04-09       Impact factor: 6.150

6.  Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.

Authors:  Jerry R Mendell; Zarife Sahenk; Samiah Al-Zaidy; Louise R Rodino-Klapac; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Natalie Miller; Mehmet Yalvac; Igor Dvorchik; Melissa Moore-Clingenpeel; Kevin M Flanigan; Kathleen Church; Kim Shontz; Choumpree Curry; Sarah Lewis; Markus McColly; Mark J Hogan; Brian K Kaspar
Journal:  Mol Ther       Date:  2017-03-06       Impact factor: 11.454

Review 7.  Advancements in magnetic resonance imaging-based biomarkers for muscular dystrophy.

Authors:  Doris G Leung
Journal:  Muscle Nerve       Date:  2019-05-14       Impact factor: 3.217

8.  Magnetic Resonance Monitoring of Disease Progression in mdx Mice on Different Genetic Backgrounds.

Authors:  Ravneet Vohra; Abhinandan Batra; Sean C Forbes; Krista Vandenborne; Glenn A Walter
Journal:  Am J Pathol       Date:  2017-09       Impact factor: 4.307

9.  Texture analysis using T1-weighted images for muscles in Charcot-Marie-Tooth disease patients and volunteers.

Authors:  Ji Hyun Lee; Young Cheol Yoon; Hyun Su Kim; Jae-Hun Kim; Byung-Ok Choi
Journal:  Eur Radiol       Date:  2020-10-30       Impact factor: 5.315

10.  T₂ mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross-sectional study of lower leg muscles in 5-15-year-old boys with Duchenne muscular dystrophy.

Authors:  Ishu Arpan; Sean C Forbes; Donovan J Lott; Claudia R Senesac; Michael J Daniels; William T Triplett; Jasjit K Deol; H Lee Sweeney; Glenn A Walter; Krista Vandenborne
Journal:  NMR Biomed       Date:  2012-10-09       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.